Clinical Research Directory
Browse clinical research sites, groups, and studies.
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis
Sponsor: Bausch Health Americas, Inc.
Summary
Prospective, Observational Study to Assess the Long-Term Safety of Brodalumab Compared with Other Therapies in the Treatment of Adults with Moderate-to-Severe Psoriasis
Official title: Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care
Key Details
Gender
All
Age Range
18 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
3500
Start Date
2017-07-25
Completion Date
2031-11
Last Updated
2025-09-16
Healthy Volunteers
Not specified
Conditions
Interventions
Brodalumab
Brodalumab
Comparator Drug (non-biologic IL-17 inhibitors)
Comparator subjects treated with non-biologic IL-17 inhibitors
Locations (1)
Registry
Bridgewater, New Jersey, United States